PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) is the pharmaceutical industry's primary lobbying organization, and in 2024 it demonstrated why it's considered the most powerful trade association in Washington. PhRMA itself spent $31.72 million on lobbying — the largest single healthcare lobbying expenditure — while its member companies collectively spent a record $387 million, making the pharmaceutical industry the most expensive lobbying force in America by a wide margin. PhRMA employs 120 registered lobbyists in Washington — more than two for every United States senator. This army of lobbyists covers every committee and subcommittee that touches drug policy, from the Senate Finance Committee that oversees Medicare to the House Energy and Commerce Committee that handles FDA authorization. The lobbyists include former members of Congress, former committee staff directors, and former FDA officials who understand the regulatory process intimately. The Billy Tauzin story remains the most infamous revolving door case in American politics. As Chairman of the House Energy and Commerce Committee, Tauzin was the lead author of the 2003 Medicare Modernization Act, which created Medicare Part D — the prescription drug benefit. Crucially, the law included a provision explicitly prohibiting Medicare from negotiating drug prices with pharmaceutical companies, a restriction that would cost American taxpayers hundreds of billions of dollars over the following two decades. Months after the bill's passage, Tauzin resigned from Congress and became president of PhRMA at a salary of approximately $2 million per year — a payment widely seen as a reward for writing the provision that guaranteed the industry's profits. For two decades, the pharmaceutical industry successfully blocked every attempt to allow Medicare to negotiate drug prices. This single policy victory was worth an estimated $500 billion to the industry over 20 years. When the Inflation Reduction Act of 2022 finally allowed limited Medicare negotiation for 10 drugs, PhRMA launched a massive legal and lobbying campaign to gut the provision, filing lawsuits in multiple jurisdictions and spending tens of millions on advertising campaigns. The industry's ability to delay this reform for 20 years — from 2003 to 2022 — represents one of the most successful lobbying campaigns in American history. PhRMA's political strategy extends beyond direct lobbying. The industry funds patient advocacy groups that serve as front organizations, mobilizing patients with specific diseases to lobby against policies that would lower drug prices. These groups often present as grassroots organizations but receive the majority of their funding from pharmaceutical companies. PhRMA also funds academic research that conveniently concludes that drug price regulation would reduce innovation — research that PhRMA-funded lobbyists then cite when arguing against regulation. Under Trump 2.0, PhRMA has boosted spending on lobbying firms with close Trump connections, recognizing that access to the White House is essential for shaping drug policy. The industry's argument — that high drug prices fund innovation — crumbles under scrutiny: pharmaceutical companies routinely spend more on marketing and lobbying than on research, and many breakthrough drugs are developed with NIH-funded research before being commercialized by private companies.